Product Description
The antisense oligonucleotide, PF-06473871, comprises a 20-nucleotide chain containing a phosphorothioate backbone and 2Õ-methoxyethyl modifications of the ribose units at the 3Õ and 5Õ ends, conferring resistance to nucleases and providing long residence in tissues. PF-06473871 targets CTGF expression and is delivered by intradermal injection to a surgical wound. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191237/)
Mechanisms of Action: CTGF Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Vision, Low|Other|Healthy Volunteers
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B5301012 | P2 |
Terminated |
Vision, Low |
2015-01-01 |
|
| 2012-004355-37 | P2 |
Completed |
Unknown |
2014-10-17 |
|
| B5301001 | P2 |
Completed |
Healthy Volunteers |
2014-10-01 |
|
| EXC 001-206 | P2 |
Completed |
Other |
2013-09-10 |